These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

481 related items for PubMed ID: 11571447

  • 1. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation.
    Bumgardner GL, Hardie I, Johnson RW, Lin A, Nashan B, Pescovitz MD, Ramos E, Vincenti F, Phase III Daclizumab Study Group.
    Transplantation; 2001 Sep 15; 72(5):839-45. PubMed ID: 11571447
    [Abstract] [Full Text] [Related]

  • 2. Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function.
    Bumgardner GL, Ramos E, Lin A, Vincenti F, Daclizumab Triple Therapy and Double Therapy Groups.
    Transplantation; 2001 Aug 27; 72(4):642-7. PubMed ID: 11544424
    [Abstract] [Full Text] [Related]

  • 3. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS.
    Health Technol Assess; 2005 May 27; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [Abstract] [Full Text] [Related]

  • 4. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
    Nashan B, Light S, Hardie IR, Lin A, Johnson JR.
    Transplantation; 1999 Jan 15; 67(1):110-5. PubMed ID: 9921806
    [Abstract] [Full Text] [Related]

  • 5. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR, Faulds D.
    Drugs; 1999 Dec 15; 58(6):1029-42. PubMed ID: 10651389
    [Abstract] [Full Text] [Related]

  • 6. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
    Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J, Johnson R, Kuypers D, Stuart F, Khanna A, Navarro M, Nashan B.
    Transplantation; 2001 May 15; 71(9):1282-7. PubMed ID: 11397963
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation.
    Ekberg H, Persson NH, Källen R, Gül-Baykurt N.
    Scand J Immunol; 2003 Dec 15; 58(6):670-7. PubMed ID: 14636424
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A.
    Paediatr Drugs; 2003 Dec 15; 5(10):699-716. PubMed ID: 14510627
    [Abstract] [Full Text] [Related]

  • 12. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation.
    Aktas S, Colak T, Baskin E, Sevmis S, Ozdemir H, Moray G, Karakayali H, Haberal M.
    Transplant Proc; 2011 Mar 15; 43(2):453-7. PubMed ID: 21440732
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Daclizumab to prevent rejection after cardiac transplantation.
    Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB, Van Bakel A, Gordon RD, Popat R, Cockey L, Mamelok RD.
    N Engl J Med; 2005 Jun 30; 352(26):2705-13. PubMed ID: 15987919
    [Abstract] [Full Text] [Related]

  • 16. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY, Liu YL, Wong KM, Chan HW, Chan YH, Wong HS, Chak WL, Choi KS, Chau KF, Shek CC, Li CS.
    Nephrology (Carlton); 2008 Jun 30; 13(3):251-5. PubMed ID: 18221256
    [Abstract] [Full Text] [Related]

  • 17. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R, Büchler M, Lepogamp P, Westeel PF, Le Meur Y, Etienne I, Lobbedez T, Toupance O, Caillard S, Goujon JM, Bergougnoux L, Touchard G.
    Nephrol Dial Transplant; 2008 Jun 30; 23(6):2024-32. PubMed ID: 18199693
    [Abstract] [Full Text] [Related]

  • 18. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group.
    Kahan BD, Rajagopalan PR, Hall M.
    Transplantation; 1999 Jan 27; 67(2):276-84. PubMed ID: 10075594
    [Abstract] [Full Text] [Related]

  • 19. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
    Ciancio G, Burke GW, Gaynor JJ, Roth D, Sageshima J, Kupin W, Tueros L, Hanson L, Rosen A, Ruiz P, Miller J.
    Transplantation; 2008 Jul 15; 86(1):67-74. PubMed ID: 18622280
    [Abstract] [Full Text] [Related]

  • 20. Daclizumab: novel biologic immunoprophylaxis for prevention of acute rejection in renal transplantation.
    Vincenti F.
    Transplant Proc; 1999 Sep 15; 31(6):2206-7. PubMed ID: 10500546
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.